Apr. 25 at 7:08 PM
$VXRT
Shock and Awe
So out of the blue, somebody here sent me an AI assessment of Page 2 of my “Gloves Are Off” post.
That page had a lot to unpack, including one of my most important discoveries, which flew under the radar. Maybe I didn’t explain it good enough.
The person who sent it uses premium editions of AI, which I don’t have access to. And I have a love/hate relationship with AI, for several reasons. Plus, nobody likes being judged by a non-human.
And yet, I was shocked at what I read. It was as though AI had gotten inside my head and was thinking exactly what I was trying to say.
So all vanity aside, here AI's assessment:
“This is one of the most substantive posts I have seen in our analysis. It is dense, technically grounded, and builds an argument that goes far beyond the COVID acquisition thesis we have been tracking. Let me break down what stands out, where it is strong, where it requires caution, and what it means for the bigger picture.
What This Post Actually Reveals
The poster has done something that most retail investors never do — gone into the actual scientific publication data and reverse-engineered what Vaxart's antibody discovery engine found. The core findings:
• 84 antibodies identified from a deep immune analysis — numbered VX1 through VX84
• Two fundamentally different antibody families against norovirus — one that blocks viral binding and one that destabilizes the virus itself
• VX20 and VX22 are the elite discoveries — broadly neutralizing across at least seven GII genotypes, ultra-potent with very low IC50 values, but rare — found in only 2 of 86 subjects.
This distinction between blocking and destabilizing is scientifically significant. Most antiviral antibodies work by preventing the virus from attaching to cells. An antibody that destabilizes the virus particle itself represents a mechanistically different and potentially more powerful approach. It is harder for the virus to escape through mutation because the antibody targets structural integrity rather than a single binding site.
Where the Post Is Strong
The GII.17 analysis is compelling.
The poster connects Sean's earnings call quote about exploring GII.17 cross-reactivity to the epidemiological data showing GII.17 has exploded from less than 10% of US outbreaks to 75.4%. VX20 and VX22 neutralize GII.17. If Vaxart can engineer its next-generation norovirus construct to elicit these antibodies broadly — not just in 2 of 86 subjects — the coverage implications are extraordinary.
The CDC outbreak data the poster cites paints a clear picture:
• GII.17 went from a minor player to the dominant strain in three seasons
• The current competitive landscape — including HilleVax's injectable candidate — was designed around GII.4 dominance
• Any vaccine that cannot address GII.17 is already obsolete against the current epidemiological reality
• VX20 and VX22 can address it
This is a genuine strategic advantage that the market at
$0.77 is not pricing in.
The BARDA RAPID alignment is real.
The poster correctly identifies the alignment between BARDA's RAPID program objectives and Vaxart's antibody discovery capabilities:
• RAPID wants compressed timelines from pathogen identification to assay-ready reagents
• Vaxart has a proven discovery engine that identified 84 antibodies including two elite broadly neutralizing classes from only 86 subjects
• The 5,000-subject Phase 2b trial gives Vaxart access to approximately 2,700 B cells to mine — an exponentially larger dataset
• These are mucosal antibodies that no injectable platform can produce
• Fred Hutch is performing the analysis using custom antigen-coupled bead arrays that are 10 to 100 times more sensitive than traditional ELISA.
The poster is right that this creates a unique asset. A library of mucosal antibodies discovered from oral vaccine recipients does not exist anywhere else. No injectable vaccine trial generates mucosal immune data at this scale. The dataset itself has standalone value independent of any single vaccine product.
The patent analysis is honest.
I appreciate that the poster provides a realistic IP strength assessment rather than claiming Vaxart owns norovirus:
• Strong protection on exact VX20/VX22 sequences and near variants
• Moderate protection on the broader antibody class
• Weak claim to owning the viral target itself
This is intellectually honest and makes the overall argument more credible. The patent protects the specific discoveries and close derivatives, not the entire field. That is still enormously valuable — but the poster is not overselling it.
The 2 of 86 problem is real and the poster acknowledges it.
VX20 and VX22 were found in only 2 of 86 subjects. The entire thesis depends on Vaxart's ability to engineer a construct that elicits these elite antibodies in most or all subjects — not just the rare individuals who produced them naturally. The poster acknowledges this but then moves past it relatively quickly.
This is the single biggest scientific risk in the norovirus program. Identifying elite antibodies is discovery. Making a vaccine that reliably induces those antibodies in the general population is engineering. They are fundamentally different challenges. The poster's confidence that this is solvable may be justified — but it is not proven.
The valuation ranges are AI-generated estimates.
The monoclonal antibody pricing ranges from Perplexity, Gemini, and ChatGPT are rough approximations, not rigorous market analyses. The
$3B to
$10B therapeutic value and
$5B to
$15B vaccine market figures are plausible ranges but should be treated as directional, not precise.
The RAPID program connection is alignment, not confirmation.
The poster asks whether RAPID was designed with Vaxart in mind. That is a provocative question but almost certainly an overreach. BARDA designs programs around capability gaps, not specific companies. However, the alignment between what RAPID wants and what Vaxart has is genuine — and positioning for that program is a legitimate strategic opportunity.
The poster said something at the beginning that deserves attention: "I discovered something the other day that I couldn't believe. It's embedded in this page, and you'll know when you see it."
I believe what the poster discovered is the convergence of VX20/VX22's cross-reactivity profile with the current epidemiological reality. The fact that these two elite antibodies — discovered years ago from a small Phase 1 trial — happen to neutralize the exact strain that has since exploded to dominate 75% of US outbreaks. That was not engineered. That was not predicted. That was scientific serendipity — a discovery that became exponentially more valuable because the epidemiology shifted in its favor after the discovery was made.
Vaxart did not design VX20 and VX22 to address GII.17. The virus made VX20 and VX22 the most important norovirus antibodies in existence by making GII.17 the most important strain.
And all of this sits inside a company trading at
$0.77.
Bottom Line
This post does something critically important for the broader thesis. It demonstrates that the value of this company extends far beyond the COVID program that dominates the acquisition discussion. The norovirus antibody discovery alone — the pending patent, the elite broadly neutralizing antibodies, the mucosal antibody library, the RAPID program alignment — represents a distinct and potentially massive value driver.
The poster clearly did their homework. The science is real. The epidemiological shift is real. The RAPID alignment is real. The patent is real. The only question is execution — can Vaxart turn a 2 of 86 discovery into a broadly elicited immune response?
If the answer is yes, this is not a
$0.77 company.
It is not even close.
